Literature DB >> 32447350

Reduced-intensity conditioning is a reasonable alternative for Philadelphia chromosome-positive acute lymphoblastic leukemia among elderly patients who have achieved negative minimal residual disease: a report from the Adult Acute Lymphoblastic Leukemia Working Group of the JSHCT.

Yu Akahoshi1, Satoshi Nishiwaki2, Yasuyuki Arai3, Kaito Harada4, Yuho Najima5, Yoshinobu Kanda1,6, Katsuhiro Shono7, Shuichi Ota8, Takahiro Fukuda9, Naoyuki Uchida10, Souichi Shiratori11, Masatsugu Tanaka12, Junji Tanaka13, Yoshiko Atsuta14, Shinichi Kako15.   

Abstract

Reduced-intensity conditioning (RIC) regimens have been widely used for allogeneic hematopoietic cell transplantation (HCT) in elderly patients. After the emergence of tyrosine kinase inhibitor (TKI), most patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph-positive ALL) now achieve negative results for minimal residual disease (MRD) at HCT. In this study, we evaluated patients aged 50 years or more with Ph-positive ALL who received TKI before HCT, achieved negative-MRD at HCT, and underwent their first allogeneic HCT between 2008 and 2017. In total, 90 and 136 patients who received myeloablative conditioning (MAC) and a RIC regimen, respectively, were included. The median age of patients with MAC and RIC was 54 and 60 years, respectively. Even in multivariate analyses, RIC was not significantly associated with overall mortality (hazard ratio [HR], 1.09; P = 0.724), hematological relapse (HR, 1.97; P = 0.170), or non-relapse mortality (HR, 0.84; P = 0.540). Subgroup analyses suggested that RIC resulted in superior overall survival due to a lower incidence of non-relapse mortality in patients with a poor performance status or a high HCT comorbidity index. In conclusion, RIC is a reasonable option for elderly patients with negative-MRD at HCT.

Entities:  

Mesh:

Year:  2020        PMID: 32447350     DOI: 10.1038/s41409-020-0951-0

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  33 in total

1.  Randomized study of reduced-intensity chemotherapy combined with imatinib in adults with Ph-positive acute lymphoblastic leukemia.

Authors:  Yves Chalandon; Xavier Thomas; Sandrine Hayette; Jean-Michel Cayuela; Claire Abbal; Françoise Huguet; Emmanuel Raffoux; Thibaut Leguay; Philippe Rousselot; Stéphane Lepretre; Martine Escoffre-Barbe; Sébastien Maury; Céline Berthon; Emmanuelle Tavernier; Jean-François Lambert; Marina Lafage-Pochitaloff; Véronique Lhéritier; Sylvie Chevret; Norbert Ifrah; Hervé Dombret
Journal:  Blood       Date:  2015-04-15       Impact factor: 22.113

2.  High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: a phase II study by the Japan Adult Leukemia Study Group.

Authors:  Masamitsu Yanada; Jin Takeuchi; Isamu Sugiura; Hideki Akiyama; Noriko Usui; Fumiharu Yagasaki; Tohru Kobayashi; Yasunori Ueda; Makoto Takeuchi; Shuichi Miyawaki; Atsuo Maruta; Nobuhiko Emi; Yasushi Miyazaki; Shigeki Ohtake; Itsuro Jinnai; Keitaro Matsuo; Tomoki Naoe; Ryuzo Ohno
Journal:  J Clin Oncol       Date:  2005-12-12       Impact factor: 44.544

3.  [Pathogenesis of chronic bronchitis from the pathologist's viewpoint].

Authors:  W Kühne
Journal:  Z Erkr Atmungsorgane Folia Bronchol       Date:  1973-05

4.  Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 study.

Authors:  Elias Jabbour; Hagop Kantarjian; Farhad Ravandi; Deborah Thomas; Xuelin Huang; Stefan Faderl; Naveen Pemmaraju; Naval Daver; Guillermo Garcia-Manero; Koji Sasaki; Jorge Cortes; Rebecca Garris; C Cameron Yin; Joseph D Khoury; Jeffrey Jorgensen; Zeev Estrov; Zachary Bohannan; Marina Konopleva; Tapan Kadia; Nitin Jain; Courtney DiNardo; William Wierda; Vicky Jeanis; Susan O'Brien
Journal:  Lancet Oncol       Date:  2015-09-30       Impact factor: 41.316

Review 5.  Minimal residual disease in adult ALL: technical aspects and implications for correct clinical interpretation.

Authors:  Monika Brüggemann; Michaela Kotrova
Journal:  Blood Adv       Date:  2017-11-28

6.  US Intergroup Study of Chemotherapy Plus Dasatinib and Allogeneic Stem Cell Transplant in Philadelphia Chromosome Positive ALL.

Authors:  Farhad Ravandi; Megan Othus; Susan M O'Brien; Stephen J Forman; Chul S Ha; Jeffrey Y C Wong; Martin S Tallman; Elisabeth Paietta; Janis Racevskis; Geoffrey L Uy; Mary Horowitz; Naoko Takebe; Richard Little; Uma Borate; Partow Kebriaei; Laura Kingsbury; Hagop M Kantarjian; Jerald P Radich; Harry P Erba; Frederick R Appelbaum
Journal:  Blood Adv       Date:  2016-12-27

7.  First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia.

Authors:  Farhad Ravandi; Susan O'Brien; Deborah Thomas; Stefan Faderl; Dan Jones; Rebecca Garris; Samuel Dara; Jeffrey Jorgensen; Partow Kebriaei; Richard Champlin; Gautam Borthakur; Jan Burger; Alessandra Ferrajoli; Guillermo Garcia-Manero; William Wierda; Jorge Cortes; Hagop Kantarjian
Journal:  Blood       Date:  2010-05-13       Impact factor: 22.113

8.  Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate.

Authors:  Deborah A Thomas; Stefan Faderl; Jorge Cortes; Susan O'Brien; Francis J Giles; Steven M Kornblau; Guillermo Garcia-Manero; Michael J Keating; Michael Andreeff; Sima Jeha; Miloslav Beran; Srdan Verstovsek; Sherry Pierce; Laurie Letvak; August Salvado; Richard Champlin; Moshe Talpaz; Hagop Kantarjian
Journal:  Blood       Date:  2003-10-09       Impact factor: 22.113

9.  Pretransplant administration of imatinib for allo-HSCT in patients with BCR-ABL-positive acute lymphoblastic leukemia.

Authors:  Shuichi Mizuta; Keitaro Matsuo; Satoshi Nishiwaki; Kiyotoshi Imai; Heiwa Kanamori; Kazuteru Ohashi; Takahiro Fukuda; Yasushi Onishi; Koichi Miyamura; Satoshi Takahashi; Makoto Onizuka; Yoshiko Atsuta; Ritsuro Suzuki; Yasuo Morishima; Koji Kato; Hisashi Sakamaki; Junji Tanaka
Journal:  Blood       Date:  2014-03-03       Impact factor: 22.113

10.  Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United States.

Authors:  Lori Muffly; Marcelo C Pasquini; Michael Martens; Ruta Brazauskas; Xiaochun Zhu; Kehinde Adekola; Mahmoud Aljurf; Karen K Ballen; Ashish Bajel; Frederic Baron; Minoo Battiwalla; Amer Beitinjaneh; Jean-Yves Cahn; Mathew Carabasi; Yi-Bin Chen; Saurabh Chhabra; Stefan Ciurea; Edward Copelan; Anita D'Souza; John Edwards; James Foran; Cesar O Freytes; Henry C Fung; Robert Peter Gale; Sergio Giralt; Shahrukh K Hashmi; Gerhard C Hildebrandt; Vincent Ho; Ann Jakubowski; Hillard Lazarus; Marlise R Luskin; Rodrigo Martino; Richard Maziarz; Philip McCarthy; Taiga Nishihori; Rebecca Olin; Richard F Olsson; Attaphol Pawarode; Edward Peres; Andrew R Rezvani; David Rizzieri; Bipin N Savani; Harry C Schouten; Mitchell Sabloff; Matthew Seftel; Sachiko Seo; Mohamed L Sorror; Jeff Szer; Baldeep M Wirk; William A Wood; Andrew Artz
Journal:  Blood       Date:  2017-07-03       Impact factor: 22.113

View more
  4 in total

1.  Dose intensity for conditioning in allogeneic hematopoietic cell transplantation: can we recommend "when and for whom" in 2021?

Authors:  Nico Gagelmann; Nicolaus Kröger
Journal:  Haematologica       Date:  2021-07-01       Impact factor: 9.941

Review 2.  MRD in ALL: Optimization and Innovations.

Authors:  Eric Pierce; Benjamin Mautner; Joseph Mort; Anastassia Blewett; Amy Morris; Michael Keng; Firas El Chaer
Journal:  Curr Hematol Malig Rep       Date:  2022-05-26       Impact factor: 4.213

Review 3.  Treatment of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia in Adults.

Authors:  Khalil Saleh; Alexis Fernandez; Florence Pasquier
Journal:  Cancers (Basel)       Date:  2022-04-01       Impact factor: 6.639

Review 4.  Potential of Mesenchymal Stem Cells in the Rejuvenation of the Aging Immune System.

Authors:  Genieve Ee Chia Yeo; Min Hwei Ng; Fazlina Binti Nordin; Jia Xian Law
Journal:  Int J Mol Sci       Date:  2021-05-27       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.